Mobic etc. (meloxicam) is a “preferential COX-2 inhibitor” nonsteroidal anti-inflammatory drug (NSAID) which was approved in 2000 (U.S FDA).
NSAID's work mainly by preventing the formation of prostaglandins, hormone-like substances which trigger pain and inflammation. Prostaglandins are produced within the body's cells by the enzyme cyclooxygenase (COX). In 1989 scientists discovered that there are two varieties of the Cox enzyme - which came to be known as COX-1 and COX-2. COX-1 is continuously secreted within the stomach and duodenum, and is important for maintaining a healthy stomach lining, normal kidney function and the clotting action of blood platelets. In contrast, the COX-2 enzyme is primarily found at sites of inflammation. The conventional, first generation NSAID's (aspirin, diclofenac, ibuprofen etc.) work by inhibiting both COX-1 and COX-2 enzymes. By blocking COX-2 they are effective in relieving pain and inflammation, but by inhibiting COX-1 they produce a much greater likelihood of gastrointestinal (GI) side effects including diarrhea, heartburn and ulcers.